YOLFTbeta
NicOx S.A.

NicOx S.A.

ALCOX · PA · Healthcare / Biotechnology

0.287EUR-0.00 (-1.03%)

Price History

Full chart

Market Stats

Previous Close0.29
Open0.297
Day Range0.2865 – 0.297
52-Week Range0.281 – 0.569
Volume82.75K
Market Cap31.26M
P/E (TTM)0.00
Forward P/E17.15
EPS-0.03
Dividend Yield0.00%
Beta0.52
50-Day Avg0.3672
200-Day Avg0.3819

About

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. It develops solutions to preserving vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, an investigational ophthalmic treatment based on fluticasone propionate that is in Phase 2 clinical trial for the treatment of dry eye disease; and NCX 1728, a NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Biot, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Gavin M. Spencer
  • Employees10
  • HeadquartersSundesk Sophia Antipolis, Biot, France, 06410, France
  • Websitehttps://www.nicox.com

Leadership

  • Dr. Gavin M. SpencerCEO & Director · b. 1969
  • Ms. Sandrine GestinVice President of Finance & Human Resources · b. 1967
  • Dr. Ramesh KrishnamoorthySenior Director and Head of Late Stage CMC & Quality Control
  • Dr. Jose BoyerConsultant
  • Mr. Doug HubatschChief Scientific Advisor · b. 1967
  • Ms. Siobhan GarbuttVice President & Head of Clinical Development

Financials

Income Statement

Currency: EUR2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue9.63M20.62M3.36M1.12M7.42M-7.61M436.00K5.98M9.96M16.00K15.08M4.72M-12.91M7.23M3.27M6.90M7.86M16.77M
Growth (%)-+114.12%-83.70%-66.72%+563.36%---94.27%+1272.02%+66.55%-99.84%+94150.00%-68.72%---43.96%-54.78%+111.04%+13.84%+113.41%
Cost of Revenue593.00K529.00K885.00K6.93M1.37M-750.00K906.00K4.71M5.98M-12.95M826.00K-12.73M17.91M17.99M18.41M1.11M10.23M
Gross Profit9.04M20.09M2.48M-5.81M6.05M-6.86M-470.00K1.27M3.98M16.00K2.13M3.89M-179.00K-10.68M-14.72M-11.50M6.75M6.54M
Gross Margin93.84%97.43%73.68%-519.12%81.50%-90.15%-107.80%21.21%39.96%100.00%14.15%82.49%-1.39%-147.62%-450.05%-166.63%85.88%38.99%
Operating Expense35.70M57.29M85.50M59.82M52.20M-15.42M14.47M28.71M30.98M20.79M19.74M25.70M-6.94M35.33M19.34M5.55M16.60M20.18M
Operating Income-26.66M-37.20M-83.03M-65.63M-46.15M-15.29M-8.56M-14.94M-27.44M-27.00M-20.77M-17.61M-21.81M-18.33M-6.76M-46.01M-34.06M-17.06M-9.85M-13.64M
Operating Margin-276.82%-180.40%-2469.57%-5864.70%-621.77%--112.41%-3427.29%-458.74%-270.99%-129812.50%-116.74%-462.37%--52.37%-636.11%-1041.30%-247.07%-125.38%-81.33%
EBITDA-26.07M-36.67M-82.14M-58.70M-44.78M-13.94M-7.82M-14.36M-25.57M-25.61M-20.77M-17.43M-21.67M-22.52M-14.12M-15.96M-21.39M-19.70M-20.56M18.91M
EBITDA Margin-270.66%-177.83%-2443.25%-5245.58%-603.27%--102.73%-3292.43%-427.48%-257.09%-129812.50%-115.61%-459.49%--109.41%-220.67%-653.87%-285.43%-261.56%112.75%
Net Income-24.70M-32.14M-73.89M-60.35M-43.95M-16.64M-10.25M-18.14M-23.16M-27.94M-19.04M-3.62M-18.39M-18.92M-18.10M-43.76M-31.29M-20.88M-22.39M-2.41M
Net Income Margin-256.45%-155.89%-2197.71%-5393.21%-592.09%--134.58%-4161.70%-387.13%-280.43%-118968.75%-23.99%-389.89%--140.22%-605.02%-956.44%-302.48%-284.90%-14.39%
R&D28.20M46.11M74.55M45.50M34.77M8.62M6.29M3.63M4.43M6.15M12.17M9.75M16.33M17.75M12.73M17.91M17.99M7.55M5.96M-
R&D as % of Total Revenue292.89%223.64%2217.34%4066.22%468.36%-82.62%833.49%74.01%61.72%76050.00%64.66%346.22%-98.61%247.62%550.05%109.40%75.82%-
Interest Expense2.00K3.00K1.00K1.00K4.00K6.00K12.00K10.00K687.00K70.00K107.00K18.00K71.00K5.09M2.21M2.02K2.14M1.63M1.56M2.95M
Interest Expense % of Total Revenue0.02%0.01%0.03%0.09%0.05%-0.16%2.29%11.48%0.70%668.75%0.12%1.51%-17.08%0.03%65.48%23.66%19.82%17.59%

Balance Sheet

Currency: EUR2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets91.40M189.45M123.62M157.43M112.89M95.83M84.15M72.18M150.04M163.35M148.75M150.80M138.59M-142.27M114.61M93.16M52.98M24.42M10.37M
Total Liabilities17.49M20.24M21.55M14.55M12.40M11.51M9.59M10.80M53.76M62.02M44.20M24.04M24.94M15.45M41.43M39.06M40.73M31.57M21.01M4.35M
Total Equity73.91M169.21M102.07M142.88M100.49M84.32M74.55M61.38M96.28M101.33M104.55M126.77M113.65M-100.83M75.55M42.29M21.41M3.41M6.02M
Cash444.00K349.00K3.05M3.15M1.58M936.00K2.41M1.04M22.62M29.07M28.86M41.39M22.06M-47.20M41.97M27.08M11.26M10.54M4.15M
Total Debt51.00K29.00K19.00K13.00K113.00K82.00K157.00K151.00K856.00K686.00K62.00K50.00K85.00K-19.07M21.51M26.51M25.15M17.74M406.33K
Net Debt-393.00K-320.00K-3.03M-3.14M-1.47M-854.00K-2.25M-885.00K-21.76M-28.38M-28.80M-41.34M-21.97M--28.12M-20.46M-569.00K13.89M7.20M-3.74M

Cash Flow

Currency: EUR2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-17.84M-29.54M-61.60M-49.86M-40.80M-14.16M-9.32M-19.44M-32.91M-22.28M-25.71M-12.41M-19.14M-16.05M-5.39M-18.48M-23.13M---
Investing Cash Flow-21.04M-3.37M7.26M12.40M-762.00K-36.00K-6.33M-5.67M3.18M4.43M8.82M60.00K-270.00K-95.00K4.95M-175.00K132.00K---
Financing Cash Flow57.55M122.22M822.00K95.81M609.00K----20.00K24.29M16.67M25.14M-22.18M19.58M13.41M8.64M---
Capital Expenditure907.00K1.38M1.43M168.00K392.00K65.00K375.00K255.00K814.00K555.00K8.00K77.00K228.00K95.00K20.00K8.00K42.00K000
Free Cash Flow-18.75M-30.91M-63.04M-50.03M-41.19M-14.22M-9.70M-19.69M-33.73M-22.84M-25.72M-12.49M-19.37M-16.15M-5.41M-18.49M-23.17M---
FCF to OCF105.08%104.66%102.33%100.34%100.96%100.46%104.02%101.31%102.47%102.49%100.03%100.62%101.19%100.59%100.37%100.04%100.18%---

Earnings

Report DateMay 11, 2007Jul 30, 2007Oct 29, 2007Mar 3, 2008May 14, 2008Jul 28, 2008Oct 22, 2008Feb 26, 2009May 13, 2009Jul 29, 2009Oct 22, 2009Mar 5, 2010May 7, 2010Jul 30, 2010Nov 3, 2010Feb 24, 2011May 4, 2011Jul 29, 2011Oct 27, 2011Feb 29, 2012May 10, 2012Jul 27, 2012Oct 25, 2012Mar 22, 2013Jul 31, 2013Oct 30, 2013Apr 2, 2014Aug 28, 2014Oct 30, 2014Mar 30, 2015Mar 31, 2017Sep 8, 2017Mar 6, 2018May 4, 2018Sep 6, 2018Oct 17, 2018Mar 6, 2019Apr 18, 2019Sep 17, 2019Oct 16, 2019Mar 6, 2020Apr 17, 2020Sep 10, 2020Oct 20, 2020Mar 1, 2021Apr 19, 2021Sep 27, 2021Oct 19, 2021Mar 10, 2022Apr 28, 2022Sep 16, 2022Oct 19, 2022Jan 18, 2023Apr 19, 2023Jul 19, 2023Oct 20, 2023Jan 25, 2024Apr 22, 2024Oct 17, 2024Dec 31, 2024Apr 30, 2025Sep 3, 2025Oct 15, 2025Dec 31, 2025
EPS Estimate--------------0.60-0.40-0.25---------0.00-0.000.000.00-0.390.000.000.000.00-0.16-0.06-0.21-0.05-0.15-0.14-0.12-0.44-0.19-0.30-0.20-0.32-0.13-0.16-0.16-0.16-0.17-0.15-0.11-0.11-0.12-0.07-0.04-0.07-0.08-0.07-0.06-0.05-0.04
EPS Actual0.16-0.77-0.65-1.68-1.18-1.84-1.52-2.20-1.02-1.44-1.16-2.38-0.50-1.40-0.65-0.50-0.28-0.26-0.18-0.430.29-0.31-0.29-0.39-0.340.00-0.320.000.000.000.00-0.480.120.00-0.260.00-0.36-0.21-0.03-0.15-0.58-0.12-0.44-0.19-0.10-0.20-0.32-0.13-0.11-0.16-0.16-0.15-0.23-0.12-0.12-0.07-0.07-0.03-0.07--0.08-0.04-0.12-
Surprise--------------133.33%-62.50%-100.00%--------------100.00%----100.00%-500.00%0.00%40.00%0.00%-314.29%0.00%0.00%0.00%66.67%0.00%0.00%0.00%31.25%0.00%0.00%11.76%-53.33%-9.09%-9.09%41.67%0.00%25.00%0.00%--14.29%33.33%-140.00%-
Timing-------------Pre-marketPre-marketPre-market------------------------------------Pre-marketPre-marketAfter-hoursPre-marketPre-market-----Pre-market-

Key Statistics & Ratios

Market Cap31.26M
Enterprise Value28.93M
Trailing P/E0.00
Forward P/E17.15
PEG Ratio6.24
Price / Sales1.86
Price / Book5.54
EPS-0.03
Book Value0.068
Revenue (TTM)16.77M
Gross Profit (TTM)6.54M
EBITDA6.64M
Profit Margin-14.39%
Operating Margin77.28%
Return on Equity-51.16%
Return on Assets23.81%
Shares Outstanding97.22M
Shares Float85.07M
Beta0.52
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Dec 3, 20151:5
  • Nov 26, 2009794:685
  • Jan 30, 20071897:1776
  • Jun 14, 2002959692:319897